201 related articles for article (PubMed ID: 18043911)
1. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Mar; 64(3):275-82. PubMed ID: 18043911
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
4. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Hemeryck A; Lefebvre RA; De Vriendt C; Belpaire FM
Clin Pharmacol Ther; 2000 Mar; 67(3):283-91. PubMed ID: 10741632
[TBL] [Abstract][Full Text] [Related]
5. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
6. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
7. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
[TBL] [Abstract][Full Text] [Related]
8. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.
Stout SM; Nielsen J; Welage LS; Shea M; Brook R; Kerber K; Bleske BE
J Clin Pharmacol; 2011 Mar; 51(3):389-96. PubMed ID: 20400652
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
10. [Bradycardia after beginning therapy with metoprolol and paroxetine].
König F; Häfele M; Hauger B; Löble M; Wössner S; Wolfersdorf M
Psychiatr Prax; 1996 Sep; 23(5):244-5. PubMed ID: 8992519
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label study.
Karlson BW; Dellborg M; Gullestad L; Aberg J; Sugg J; Herlitz J
Cardiology; 2014; 127(2):73-82. PubMed ID: 24247812
[TBL] [Abstract][Full Text] [Related]
12. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
[TBL] [Abstract][Full Text] [Related]
13. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
14. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
17. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.
Bahar MA; Kamp J; Borgsteede SD; Hak E; Wilffert B
Br J Clin Pharmacol; 2018 Dec; 84(12):2704-2715. PubMed ID: 30248178
[TBL] [Abstract][Full Text] [Related]
18. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
19. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
Solai LK; Pollock BG; Mulsant BH; Frye RF; Miller MD; Sweet RA; Kirshner M; Sorisio D; Begley A; Reynolds CF
J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
[TBL] [Abstract][Full Text] [Related]
20. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
Rau T; Heide R; Bergmann K; Wuttke H; Werner U; Feifel N; Eschenhagen T
Pharmacogenetics; 2002 Aug; 12(6):465-72. PubMed ID: 12172215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
